Bioventix PLC (LON:BVXP - Get Free Report) insider Bruce Hiscock purchased 66 shares of the company's stock in a transaction dated Monday, April 27th. The shares were bought at an average cost of GBX 1,679 per share, for a total transaction of £1,108.14.
Bioventix Stock Down 2.9%
Shares of LON BVXP traded down GBX 50 during trading on Tuesday, reaching GBX 1,650. 36,078 shares of the company traded hands, compared to its average volume of 10,859. The firm has a 50 day simple moving average of GBX 1,602.69 and a 200-day simple moving average of GBX 1,823.75. The stock has a market capitalization of £86.21 million, a PE ratio of 11.74 and a beta of 0.48. Bioventix PLC has a 52-week low of GBX 1,300 and a 52-week high of GBX 3,020.
Bioventix (LON:BVXP - Get Free Report) last announced its quarterly earnings results on Monday, March 30th. The biotechnology company reported GBX 69.38 earnings per share (EPS) for the quarter. The firm had revenue of GBX 615.88 billion for the quarter. Bioventix had a net margin of 59.30% and a return on equity of 65.83%. As a group, research analysts predict that Bioventix PLC will post 166.3066955 EPS for the current year.
About Bioventix
(
Get Free Report)
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; and Pyrene (HOP-G) ELISA kit to monitor human exposure to industrial pollutants. It also provides contract SMAs and recombinant services. Bioventix PLC was incorporated in 2003 and is based in Farnham, United Kingdom.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bioventix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bioventix wasn't on the list.
While Bioventix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
